

REVIEW ARTICLE OPEN



Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Mohamed Amgad et al.[#]

Assessment of tumor-infiltrating lymphocytes (TILs) is increasingly recognized as an integral part of the prognostic workflow in triple-negative (TNBC) and HER2-positive breast cancer, as well as many other solid tumors. This recognition has come about thanks to standardized visual reporting guidelines, which helped to reduce inter-reader variability. Now, there are ripe opportunities to employ computational methods that extract spatio-morphologic predictive features, enabling computer-aided diagnostics. We detail the benefits of computational TILs assessment, the readiness of TILs scoring for computational assessment, and outline considerations for overcoming key barriers to clinical translation in this arena. Specifically, we discuss: 1. ensuring computational workflows closely capture visual guidelines and standards; 2. challenges and thoughts standards for assessment of algorithms including training, preanalytical, analytical, and clinical validation; 3. perspectives on how to realize the potential of machine learning models and to overcome the perceptual and practical limits of visual scoring.

npj Breast Cancer (2020)6:16; <https://doi.org/10.1038/s41523-020-0154-2>

INTRODUCTION

Very large adjuvant trials have illustrated how the current schemes fail to stratify patients with sufficient granularity to permit optimal selection for clinical trials, likely owing to application of an overly limited set of clinico-pathologic features^{1,2}. Histologic evaluation of tumor-infiltrating lymphocytes (TILs) is emerging as a promising biomarker in solid tumors and has reached level IB-evidence as a prognostic marker in triple-negative (TNBC) and HER2-positive breast cancer^{3–5}. Recently, the St Gallen Breast Cancer Expert Committee endorsed routine assessment of TILs for TNBC patients⁶. In the absence of adequate standardization and training, visual TILs assessment (VTA) is subject to a marked degree of ambiguity and interobserver variability^{7–9}. A series of published guidelines from this working group (also known as TIL Working group or TIL-WG) aimed to standardize VTA in solid tumors, to improve reproducibility and clinical adoption^{10–12}. TIL-WG is an international coalition of pathologists, oncologists, statisticians, and data scientists that standardize the assessment of Immuno-Oncology Biomarkers to aid pathologists, clinicians, and researchers in their research and daily practice. The value of these guidelines was highlighted in two studies systematically examining VTA reproducibility^{7,13}. Nevertheless, VTA continues to have inherent limitations that cannot be fully addressed through standardization and training, including: 1. visual assessment will always have some degree of inter-reader variability; 2. the time constraints of routine practice make comprehensive assessment of large tissue sections challenging^{7,13}; 3. perceptual limitations may introduce bias in VTA, for example, the same TILs density is perceived to be higher if there is limited stroma.

Research in using machine learning (ML) algorithms to analyze histology has recently produced encouraging results, fueled by improvements in both hardware and methodology. Algorithms that learn patterns from labeled data, based on “deep learning” neural networks, have obtained promising results in many challenging problems. Their success has translated well to digital

pathology, where they have demonstrated outstanding performance in tasks like mitosis detection, identification of metastases in lymph node sections, tissue segmentation, prognostication, and computational TILs assessment (CTA)^{14–17}. ‘Traditional’ computational analysis of histology focuses on complex image analysis routines, that typically require extraction of handcrafted features and that often do not generalize well across data sets^{18,19}. Although studies utilizing deep learning-based methods suggest impressive diagnostic performance, and better generalization across data sets, these methods remain experimental. Table 1 shows a sample of published CTA algorithms and discusses their strengths and limitations, in complementarity with a previous literature review by the TIL-WG^{16,20–31}.

This review and perspective provides a broad outline of key issues that impact the development and translation of computational tools for TILs assessment. The ideal intended outcome is that CTA is successfully integrated into the routine clinical workflow; there is significant potential for CTA to address inherent limitations in VTA, and partially to mitigate high clinical demands in remote and under-resourced settings. This is not too difficult to conceive, and there are documented success stories in the commercialization and clinical adoption of computational algorithms including pap smear cytology analyzers³², blood analyzers³³, and automated immunohistochemistry (IHC) workflows for ER, PR, Her2, and Ki67^{34–38}.

THE IMPACT OF STAINING APPROACH ON ALGORITHM DESIGN AND DEPLOYMENT

The type of stain and imaging modality will have a significant impact on algorithm design, validation, and capabilities. VTA guideline from the TIL-WG focus on assessment of stromal TILs (sTIL) using hematoxylin and eosin (H&E)-stained formalin-fixed paraffin-embedded sections, given their practicality and widespread availability, and the clear presentation of tissue

[#]A full list of authors and their affiliations appears at the end of the paper.

Table 1. Sample CTA algorithms from the published literature.

Stain Approach	Ref	Data set	Method	Ground truth	Notes
H&E Patch classification	²⁴	Multiple sites TCGA data set	CNN	Labeled patches (yes/no TILs) Annotations are open-access	Strengths: large-scale study with investigation of spatial TIL maps. AV includes molecular correlates. Limitations: does not distinguish sTIL and iTIL; does not classify individual TILs*. Other: we defined CTA TIL score as fraction of patches that contain TILs, and found this to be correlated with VTA ($R = 0.659$, $p = 2e-35$).
Semantic segmentation	¹⁶	Breast TCGA data set	FCN	Traced region boundaries (exhaustive) Annotations are open-access	Strengths: large sample size and regions; investigates inter-rater variability at different experience levels; delineation of tumor, stroma and necrosis regions. Limitations: only detects dense TIL infiltrates*; does not classify individual TILs*.
Semantic segmentation + Object detection	²⁵	Breast	Seeding + FCN	Traced region boundaries (exhaustive)	Strengths: mostly follows TIL-WG VTA guidelines. AV includes correlation with consensus VTA scores and inter-pathologist variability.
Object detection	²⁶	Breast Private data set	SVM using morphology features	Labeled & segmented nuclei within labeled region Labeled nuclei	Limitations: heavy ground truth requirement*; underpowered CV; and limited manually annotated slides. Strengths: robust analysis and exploration of molecular TIL correlates.
Object detection	²⁷	Breast Private data set	RG and MRF	Qualitative density scores Labeled patches (low-medium-high density)	Limitations: individual labeled nuclei are limited; does not distinguish TILs in different histologic regions*. Strengths: explainable model and modular pipeline.
Object detection	²⁸	NSCLC	Watershed + SVM classifier	Labeled nuclei	Limitations: does not distinguish sTIL and iTIL; does not classify individual TILs. Limited AV sample size. Strengths: explainable model; robust CV; captures spatial TIL clustering.
Object detection + inferred TIL localization	³¹	Private data sets Breast	SVM classifier using morphology features	Labeled nuclei	Limitations: limited AV; does not distinguish sTIL and iTIL. Strengths: infers TIL localization using spatial localization. Robust CV. Investigation of spatial TIL patterns.
IHC Object detection + manual regions	²⁹	Colon Private data set	Complex pipeline (non-DL)	Qualitative density scores Overall density estimates	Limitations: individual labeled nuclei are limited. not clear if spatial clustering has 1:1 correspondence with regions. Strengths: CTA within manual regions, including invasive margin. Limitations: unpublished AV.
Object detection	³⁰	Multiple Private data set	Multiple DL pipelines	Labeled nuclei within FOV (exhaustive)	Strengths: large-scale, robust AV. Systematic benchmarking. Limitations: no CV; does not distinguish TILs in different regions*.

This non-exhaustive list has been restricted to H&E and chromogenic IHC, although excellent works exist showing CTA based on other approaches like multiplexed immunofluorescence^{21–23}. Published CTA algorithms vary markedly in their approach to TIL scoring, the robustness of their validation, their interpretability, and their consistency with published VTA guidelines. Strengths and limitations of each publication is highlighted, with general limitations (related to the broad approach used, not the specific paper) are marked with an asterisk (*). Going forward, nuanced approaches are needed, ideally incorporating workflows for robust quantification and validation as presented in this paper. Different approaches have different ground truth requirements (illustrated in Fig. 1, panel f), hence the need for large-scale ground truth data sets. We encourage all future CTA publications to open-access their data sets whenever possible. Of note are two major efforts: 1. A group of scientists, including the US FDA and the TIL-WG, is collaborating to crowdsourcing pathologists and collect images and pathologist annotations that can be qualified by the FDA medical device development tool program; 2. The TIL-WG is organizing a challenge to validate CTA algorithms against clinical trial outcome data (CV).
AV analytical validation, CNN convolutional neural network, DL deep learning, FCN fully convolutional network, FOV field of view, MRF markov random field, RG region growing, NSCLC non-small cell lung cancer, SVM support vector machine.

architecture this stain provides^{10–12,39}. Multiple studies have relied on in situ approaches like IHC, in situ hybridization (ISH), or genomic deconvolution in assessing TILs^{11,40,41}. These modalities, however, are not typically used in daily clinical TILs assessment, as they are either still experimental, rely on assays of variable

reliability, or involve stains not widely used in clinical practice, especially in low-income settings^{4,10,11}. It is also difficult to quantitate and establish consistent thresholds for IHC measurement of even well-defined epitopes, such as Ki67 and ER, between different labs^{42,43}. Moreover, there is no single IHC stain that




Fig. 1 Outline of the visual (VTA) and computational (CTA) procedure for scoring TILs in breast carcinomas. TIL scoring is a complex procedure, and breast carcinomas are used as an example. Specific guidelines for scoring different tumors are provided in the references. Steps involved in VTA and/or CTA are tagged with these abbreviations. CTA according to TIL-WG guidelines involves TIL scoring in different tissue compartments. **a** Invasive edge is determined (red) and key confounding regions like necrosis (yellow) are delineated. **b** Within the central tumor, tumor-associated stroma is determined (green). Other considerations and steps are involved depending on histologic subtype, slide quality, and clinical context. **c** Determination of regions for inclusion or exclusion in the analysis in accordance with published guidelines. **d** Final score is estimated (visually) or calculated (computationally). In breast carcinomas, stromal TIL score (sTIL) is used clinically. Intratumoral TIL score (iTIL) is subject to more VTA variability, which has hampered the generation of evidence demonstrating prognostic value; perhaps CTA of iTILs will prove less variable and, consequently, prognostic. **e** The necessity of diverse pathologist annotations for robust analytical validation of computational models. Desmoplastic stroma may be misclassified as tumor regions; Vacuolated tumor may be misclassified as stroma; intermixed normal acini or ducts, DCIS/LCIS, and blood vessels may be misclassified as tumor; plasma cells are sometimes misclassified as carcinoma cells. Note that while the term “TILs” includes lymphocytes, plasma cells and other small mononuclear infiltrates, lumping these categories may not be optimal from an algorithm design perspective; plasma cells tend to be morphologically different from lymphocytes in nuclear texture, size, and visible cytoplasm. **f** Various computational approaches may be used for computational scoring. The more granular the algorithm is, the more accurate/useful it is likely to be, but—as a trade-off—the more it relies on exhaustive manual annotations from pathologists. The least granular approach is patch classification, followed by region delineation (segmentation), then object detection (individual TILs). A robust computational scoring algorithm likely utilizes a combination of these (and related) approaches.

highlights all mononuclear cells with high sensitivity and specificity, so H&E remains the stain typically used in the routine clinical setting⁴⁴.

Despite these issues, there are significant potential advantages for using IHC with CTAs. By specifically staining TILs, IHC can make image analysis more reliable, and can also present new opportunities for granular TILs subclassification; different TIL subpopulations, including CD4+ T cells, CD8+ T cells, Tregs, NK cells, B cells, etc, convey pertinent information on immune activation and repression^{4,12}. IHC is already utilized in standardization efforts for TILs assessment in colorectal carcinomas^{45,46}. The specific highlighting of TILs by IHC can improve algorithm specificity^{47,48}, and enable characterization of TIL subpopulations that have potentially distinct prognostic or predictive roles^{49,50}. IHC can reduce misclassification of intratumoral TILs, which are difficult to reliably assess given their resemblance to tumor or supporting cells in many contexts like lobular breast carcinomas, small-blue-cell tumors like small cell lung cancer, and primary brain tumors^{4,12}.

CHARACTERISTICS OF CTA ALGORITHMS THAT CAPTURE CLINICAL GUIDELINES

TIL-WG guidelines for VTA are somewhat complex^{4,10–12}. There are VTA guidelines for many primary solid tumors and metastatic tumor deposits^{10,12}, for untreated infiltrating breast carcinomas¹¹, post-neoadjuvant residual carcinomas of the breast³⁹, and for carcinoma in situ of the breast³⁹. TILs score is defined as the fraction of a tissue compartment that is occupied by TILs (lymphoplasmacytic infiltrates). Different compartments have different prognostic relevance; tumor-associated sTILs is the most relevant in most solid tumors, whereas intratumoral TIL score (iTILs) has been reported to be prognostic, most notably in melanoma¹⁰. The spatial and visual context of TILs is strongly confounded by organ site, histologic subtype, and histomorphologic variables; therefore, it is important to provide situational context and instructions for clinical use of the CTA algorithms^{24,51,52}. For example, a CTA algorithm designed for general-purpose breast cancer TILs scoring should be validated on different subtypes (infiltrating ductal, infiltrating lobular, mucinous, etc) and on a wide array of slides that capture variabilities in tumor phenotype (e.g., vacuolated tumor, necrotic tumor, etc), stromal phenotype (e.g., desmoplastic stroma), TIL densities, and sources of variability like staining and artifacts. That being said, it is plausible to assume that the biology and significance of TILs may vary in different clinical and genomic subtypes of the same primary cancer site, and that a general-purpose TILs-scoring algorithm may not be applicable. Further research into the commonalities and differences in

the prognostic and biological value of TILs in different tissue sites and within different subtypes of the same cancer is warranted.

Clear inclusion criteria are helpful in deciding whether a slide is suitable for a particular CTA algorithm. For robust implementation, it is useful to: 1. detect when slides fail to meet its minimum quality; 2. provide some measure of confidence in its predictions; 3. be free of single points of failure (i.e., modular enough to tolerate failure of some sub-components); 4. be somewhat explainable, such that an expert pathologist can understand its limitations, common failure modes, and what the model seems to rely on in making decisions. Algorithms for measuring image quality and detecting artifacts will play an important role in the clinical implementation of CTA⁵³.

From a computer vision perspective, we can subdivide CTA in two separate tasks: 1. segmentation of the region of interest (e.g., intratumoral stroma in case of sTIL assessment) and 2. detection of individual TILs within that region. In practice, a set of complementary computer vision problems often need to be addressed to score TILs (Fig. 1). To segment the region in which TILs will be assessed, it is also often needed to explicitly segment regions for exclusion from the analysis. Although these can be manually annotated by pathologists, these judgements are a significant source of variability in VTA, and developing algorithms capable of performing these tasks could improve reproducibility and standardization^{7–9}.

Specifically, segmentation of the “central tumor” and the “invasive margin/edge” enable TILs quantitation to be focused in relevant areas, excluding “distant” stroma along with normal tissue and surrounding structures. A semi-precise segmentation of invasive margin also allows sTILs score to be broken down for the margin and central tumor regions (especially, in colorectal carcinomas) and to characterize peri-tumoral TILs independently¹⁰. Within the central tumor, segmenting carcinoma cell nests and intratumoral stroma enables separate measurements for sTIL and iTIL densities. Furthermore, segmentation helps exclude key confounder regions that need to be excluded from the analysis. This includes necrosis, tertiary lymphoid structures, intermixed normal tissue or DCIS/LCIS (in breast carcinoma), pre-existing lymphoid stroma (in lymph nodes and oropharyngeal tumors), perivascular regions, intra-alveolar regions (in lung), artifacts, etc. This step requires high-quality segmentation annotations, and may prove to be challenging. Indeed, for routine clinical practice, it may be necessary to have a pathologist perform a quick visual confirmation of algorithmic region segmentations, and/or create high-level region annotations that may be difficult to produce algorithmically.

When designing a TIL classifier, consideration of key confounding cells is important. Although lymphocytes are, compared with

tumor cells, relatively monomorphic, their small sizes offer little lymphocyte-specific texture information; small or perpendicular cut stromal cells and even prominent nucleoli may result in misclassifications. Apoptotic bodies, necrotic debris, neutrophils, and some tumor cells (especially in lobular breast carcinomas and small-blue-round cell tumors) are other common confounders. Quantitation of systematic misclassification errors is warranted; some misclassifications will have contradictory consequences for clinical decision making. For example, neutrophils are evidently associated with adverse clinical outcomes, whereas TILs are typically associated with favorable outcomes⁵¹. Note that some of the TIL-WG clinical guidelines have been optimized for human scoring and are not very applicable in CTA algorithm design. For example, in breast carcinomas it is advised to “include but not focus on” tumor invasive edge TILs and TILs “hotspots”; CTA circumvents the need to address these cognitive biases¹¹. To fully adhere to clinical guidelines, segmentation of TILs is warranted, so that the fraction of intratumoral stroma occupied by TILs is calculated.

COMPUTER-AIDED VERSUS FULLY AUTOMATED TILS ASSESSMENT

The extent to which computational tools can be used to complement clinical decision making is highly context-dependent, and is strongly impacted by cancer type and clinical setting^{54–57}. In a computer-aided diagnosis paradigm, CTA is only used to provide guidance and increase efficiency in the workflow by any combination of the following: 1. calculating overall TILs score estimates to provide a frame-of-reference for the visual estimate; 2. directing the pathologist attention to regions of interest for TIL scoring, helping mitigate inconsistencies caused by heterogeneity in TILs density in different regions within the same slide; 3. providing a quantitative estimate for TILs density within regions of interest that the pathologist identifies, hence reducing ambiguity in visual estimation. Two models exist to assess this type of workflow during model development. In the traditional open assessment framework, the algorithm is trained on a set of manually annotated data points and evaluated on an independent held-out testing set. Alternatively, a closed-loop framework may be adopted, whereby pathologists can use the algorithmic output to re-evaluate their original decisions on the held-out set after exposure to the algorithmic results^{55,56}. Both frameworks have pros and cons, although the closed-loop framework enables assessment of the potential impact that CTA has on altering the clinical decision-making process⁵⁶.

The alternative paradigm is an entirely computational pipeline for CTA. This approach clearly provides efficiency gains, which could markedly reduce costs and accelerate development in a research setting. When the sample sizes are large enough, a few failures (i.e., “noise”) could be tolerated without altering the overall conclusions. This is contrary to clinical medicine, where CTA is expected to be highly dependable for each patient, especially when it is used to guide treatment decisions. Owing to the highly consequential nature of medical decision-making, a stand-alone CTA algorithm requires a higher bar for validation. It is also likely that even validated stand-alone CTA tools will need “sanity checks” by pathologists, guarding against unexpected failures. For example, a CTA report may be linked to a WSI display system to visualize the intermediate results (i.e., detected tissue boundaries and TILs locations) that were used by the algorithm to reach its decision (Fig. 2).

We do not envision computational models at their current level of performance replacing pathologist expertise. In fact, we would argue that quite the opposite is true; CTA enables objective quantitative assessment of an otherwise ambiguous metric, enabling the pathologist to focus more of his/her time on higher-order decision-making tasks⁵⁴. With that in mind, we argue

that the efficiency gains from CTA in under-resourced settings are likely to be derived from workflow efficiency, as opposed to reducing the domain expertise required to make diagnostic and therapeutic assessments. When used in a telepathology setting, i.e., off-site review of WSIs, CTA is still likely to require supervision by an experienced attending pathologist. Naturally, this depends on infrastructure, and one may argue that the cost-effectiveness of CTA is determined by the balance between infrastructure costs (WSI scanners, computing facilities, software, cloud support, etc) and expected long-term efficiency gains.

VALIDATION AND TRAINING ISSUES SURROUNDING COMPUTATIONAL TIL SCORING

CTA algorithms will need to be validated just like any prognostic or predictive biomarker to demonstrate preanalytical validation (Pre-AV), analytical validation (AV), clinical validation (CV), and clinical utility^{8,58,59}. In brief, Pre-AV is concerned with procedures that occur before CTA algorithms are applied, and include items like specimen preparation, slide quality, WSI scanner magnification and specifications, image format, etc; AV refers to accuracy and reproducibility; CV refers to stratification of patients into clinically meaningful subgroups; clinical utility refers to overall benefit in the clinical setting, considering existing methods and practices. Other considerations include cost-effectiveness, implementation feasibility, and ethical implications⁵⁹. VTA has been subject to extensive AV, CV, and clinical utility assessment, and it is critical that CTA algorithms are validated using the same high standards^{7,8}. The use-case of a CTA algorithm, specifically whether it is used for computer-aided assessment or for largely unsupervised assessment, is a key determinant of the extent of required validation. Key resources to consult include: 1. Recommendations by the Society for Immunotherapy of Cancer, for validation of diagnostic biomarkers; 2. Guidance documents by the US Food and Drug Administration (FDA); 3. Guidelines from the College of American Pathologists, for validation of diagnostic WSI systems^{60–64}. Granted, some of these require modifications in the CTA context, and we will highlight some of these differences here.

Pre-AV is of paramount importance, as CTA algorithm performance may vary in the presence of artifacts, variability in staining, tissue thickness, cutting angle, imaging, and storage^{65–68}. Trained pathologists, on the other hand, are more agile in adapting to variations in tissue processing, although these factors can still impact their visual assessment. Some studies have shown that the implementation of a DICOM standard for pathology images can improve standardization and improve interoperability if adopted by manufacturers^{67,69}. Techniques for making algorithms robust to variations, rather than eliminating the variations, have also been widely studied and are commonly employed^{69–72}. According to CAP guidelines, it is necessary to perform in-house validation of CTAs in all pathology laboratories, to validate the entire workflow (i.e., for each combination of tissue, stain, scanner, and CTA) using adequate sample size representing the entire diagnostic spectrum, and to re-validate whenever a significant component of the pre-analytic workflow changes⁶². Pre-AV and AV are most suitable in the in-house validation setting, as they can be performed with relatively fewer slides. It may be argued that proper in-house Pre-AV and AV suffice, provided large-scale prospective (or retrospective-prospective) AV, CV, and Clinical Utility studies were performed in a multi-center setting. Demonstrating local equivalency of Pre-AV and AV results can thus allow “linkage” to existing CV and Clinical Utility results assuming comparable patient populations.

AV typically involves quantitative assessment of CTA algorithm performance using ML metrics like segmentation or classification accuracy, prediction vs truth error, and area under receiver-operator characteristic curve or precision-recall curves. AV also includes validation against “non-classical” forms of ground truth like


Patient Name / ID: DOE, Jane / AQH12CR3-DX-2 21/05/2020 03:22 PM Gender: Female Age: 46 Dx: Breast carcinoma, right, primary; Stage IB Tx: Not initiated, No NACT Histology: Invasive ductal carcinoma / NST; Grade 3 Stain: H&E, FFPE Other Markers: TN (ER-, PR-, Her2-); Ki67 < 25%				
	Global density: Whole-slide score	Local density: 50 μm x 50 μm Fields	Local density: 100 μm x 100 μm Fields	Local density: 200 μm x 200 μm Fields
Stromal TILs	40.3 %	54.2 (\pm 20.1) %	52.1 (\pm 7.4) %	41.2 (\pm 5.1) %
Intra-tumoral TILs	5.6 %	0.1 (\pm 3.1) %	2.5 (\pm 2.1) %	4.9 (\pm 1.1) %
Invasive margin TILs	7.8 %	3.7 (\pm 4.1) %	6.2 (\pm 2.6) %	8.2 (\pm 0.8) %
Tissue delineation confidence: 0.95 TIL classification confidence: 0.86 TIL heatmap: See right; refer to WSI display for detailed tissue delineation, TIL classification, and zoomable heatmap. Distance from stromal TIL to nearest tumor: 62.1 (\pm 23.7) μm Distance from tumor to nearest TIL: 726.9 (\pm 13.5) μm Number of TIL clusters per unit area: 1.3 / mm^2 TIL cluster morphology: Brisk, diffuse - moderate heterogeneity TIL cluster size: 320 (\pm 129) μm Multivariable PFS prob.: 0.87 (1 yr) - 0.76 (3 yrs) - 0.67 (5 yrs) - 0.61 (10 yrs)				
On visual inspection, what is the quality of computational <u>tissue delineation</u> (tumor, stroma, etc) (circle one): <div style="display: flex; justify-content: center; gap: 10px;"> Very Poor Poor Acceptable Very good Excellent </div>				
On visual inspection, what is the quality of computational <u>TIL localization</u> (circle one): <div style="display: flex; justify-content: center; gap: 10px;"> Very Poor Poor Acceptable Very good Excellent </div>				
Pathologist Comments & Recommendations: <div style="border: 1px solid black; padding: 10px; min-height: 40px;"> None. Refer to pathology report for detailed histologic comment. </div>				
_____ Attending pathologist				

Fig. 2 Conceptual pathology report for computational TIL assessment (CTA). CTA reports might include global TIL estimates, broken down by key histologic regions, and estimates of classifier confidence. CTA reports are inseparably linked to WSI viewing systems, where algorithmic segmentations and localizations supporting the calculated scores are displayed for sanity check verification by the attending pathologist. Other elements, like local TIL estimates, TIL clustering results, and survival predictions may also be included.

co-registered IHC, in which case the registration process itself may also require validation. AV is a necessary prerequisite to CV as it answers the more fundamental question: “Do CTA algorithms detect TILs correctly?”. AV should measure performance over the spectrum of variability induced by pre-analytic factors, and in cohorts that reflect the full range of intrinsic/biological variability. Naturally, this means that uncommon or rare subtypes of patterns are harder to validate owing to sample size limitations. AV of nucleus detection and classification algorithms has often neglected these issues, focusing on a large number of cells from a small number of cases.

Demonstrating the validity and generalization of prediction models is a complex process. Typically, the initial focus is on “internal” validation, using techniques like split-sample cross validation and bootstrapping. Later, the focus shifts to “external” validation, i.e., on an independent cohort from another institution. A hybrid technique called “internal–external” (cross-) validation may be appropriate when multi-institutional data sets (like the TCGA and METABRIC) are available, where training is performed on some hospitals/institutions and validation is performed on

others. This was recommended by Steyerberg and Harrell and used in some computational pathology studies^{16,73–75}.

Many of the events associated with cancer progression and subtyping are strongly correlated, so it may not be enough to show correspondence between global/slide-level CTA and VTA scores, as this shortcuts the AV process⁴⁹. AV therefore relies on the presence of quality “ground truth” annotations. Unfortunately, there is a lack of open-access, large-scale, multi-institutional histology segmentation and/or TIL classification data sets, with few exceptions^{16,24,76,77}. To help address this, a group of scientists, including the US FDA Center for Devices and Radiological Health (CDRH) and the TIL-WG, is collaborating to crowdsource pathologists and collect images and pathologist annotations that can be qualified by the FDA/CDRH medical device development tool program (MDDT). The MDDT qualified data would be available to any algorithm developer to be used for the analytic evaluation of their algorithm performance in a submission to the FDA/CDRH⁷⁸. The concept of “ground truth” in pathology can be vague and is often subjective, especially when dealing with H&E; it is therefore important to measure inter-rater variability by having multiple

experts annotate the same regions and objects^{7,8}. A key bottleneck in this process is the time commitment of pathologists, so collaborative, educational and/or crowdsourcing settings can help circumvent this limitation^{16,79}. It should be stressed, however, that although annotations from non-pathologists or residents may be adequate for CTA algorithm training; validation may require ground truth annotations created or reviewed by experienced practicing pathologists^{16,80}.

It is important to note that the ambiguity in ground truth (even if determined by consensus by multiple pathologists) typically warrants additional validation using objective criteria, most notably the ability to predict concrete clinical endpoints in validated data sets. One of the best ways to meet this validation bar is to use WSIs from large, multi-institutional randomized-controlled trials. To facilitate this effort, the TIL-WG is establishing strategic international partnerships to organize a machine learning challenge to validate CTA algorithms using clinical trials data. The training sets would be made available for investigators to train and fine tune their models, whereas separate blinded validation sets would only be provided once a locked-down algorithm has been established. Such resources are needed so that different algorithms and approaches can be directly compared on the same, high-quality data sets.

CTA FOR CLINICAL VERSUS ACADEMIC USE

Like VTA, CTA may be considered to fall under the umbrella of “imaging biomarkers,” and likely follows a similar validation roadmap to enable clinical translation and adoption^{38,81,82}. CTA may be used in the following academic settings, to name a few: 1. as a surrogate marker of response to experimental therapy in animal models; 2. as a diagnostic or predictive biomarker in retrospective clinical studies using archival WSI data; 3. as a diagnostic or predictive biomarker in prospective randomized-controlled trials. Incorporation of imaging biomarkers into prospective clinical trials requires some form of analytical and clinical validation (using retrospective data, for example), resulting in the establishment of Standards of Practice for trial use⁸¹. Establishment of clinical validity and utility in multicentric prospective trials is typically a prerequisite for use in day-to-day clinical practice. In a research environment, it is not unusual for computational algorithms to be frequently tweaked in a closed-loop fashion. This tweaking can be as simple as altering hyperparameters, but can include more drastic changes like modifications to the algorithm or (inter)active machine learning^{83,84}. From a standard regulatory perspective, this is problematic as validation requires a defined “lockdown” and version control; any change generally requires at least partial re-validation^{64,85}. It is therefore clear that the most pronounced difference between CTA use in basic/retrospective research, prospective trials, and routine clinical setting is the rigor of validation required^{38,81,82}.

In a basic/retrospective research environment, there is naturally a higher degree of flexibility in adopting CTA algorithms. For example, all slides may be scanned using the same scanner and using similar tissue processing protocols. In this setting, there is no immediate need for worrying about algorithm generalization performance under external processing or scanning conditions. Likewise, it may not be necessary to validate the model using ground truth from multiple pathologists, especially if some degree of noise can be tolerated. Operational issues and practicality also play a smaller role in basic/retrospective research settings; algorithm speed and user friendliness of a particular CTA algorithm may not be relevant when routine/repetitive TILs assessment is not needed. Even the nature of CTA algorithms may be different in a non-clinical setting. For instance, even though there is conflicting evidence on the prognostic value of iTILs in breast cancer, there are motivations to quantify them in a research environment. It should be noted, however, that this

flexibility is only applicable for CTA algorithms that are being used to support non-clinical research projects, not for those algorithms that are being validated for future clinical use.

THE FUTURE OF COMPUTATIONAL IMAGE-BASED IMMUNE BIOMARKERS

CTA algorithms can enable characterization of the tumor microenvironment beyond the limits of human observers, and will be an important tool in identifying latent prognostic and predictive patterns of immune response. For one, CTA enables calculation of local TIL densities at various scales, which may serve as a guide to “pockets” of differential immune activation (Fig. 2). This surpasses what is possible with VTA and such measurements are easy to calculate provided that CTA algorithms detect TILs with adequate sensitivity and specificity. Several studies have identified genomic features that in hindsight are associated with TILs, and CTA presents opportunities for systematic investigation of these associations^{24,26,74,86,87}. The emergence of assays and imaging platforms for multiplexed immunofluorescence and in situ hybridization will present new horizons for identifying predictive immunologic patterns and for understanding the molecular basis of tumor-immune interactions^{88,89}; these approaches are increasingly becoming commoditized.

Previous work examined how various spatial metrics from cancer-associated stroma relate to clinical outcomes, and similar concepts can be borrowed; for example, metrics capturing the complex relationships between TILs and other cells/structures in the tumor microenvironment⁹⁰. CTA may enable precise definitions of “intratumoral stroma”, for example using a quantitative threshold (i.e., “stroma within x microns from nearest tumor nest”). Similar concepts could be applied when differentiating tertiary lymphocytic aggregates, or other TIL hotspots, from infiltrating TILs that presumably have a direct role in anticancer response. It is also important to note that lymphocytic aggregation and other higher-order quantitative spatial metrics may play important prognostic roles yet to be discovered. A CTA study identified five broad categories of spatial organization of TILs infiltration, which are differentially associated with different cancer sites and subtypes²⁴. Alternatively, TILs can be placed on a continuum, such that sTILs that have a closer proximity to carcinoma nests get a higher weight. iTILs could be characterized using similar reasoning. Depending on available ground truth, numerous spatial metrics can be calculated. Nuanced assessment of immune response can be performed; for example, number of apoptotic bodies and their relation to nearby immune infiltrates. It is likely that there would be a considerable degree of redundancy in the prognostic value of CTA metrics; such redundancy is not uncommon in genomic biomarkers⁹¹. This should not be problematic as long as statistical models properly account for correlated predictors. In fact, the ability to calculate numerous metrics for a very large volume of cases enables large-scale, systematic discovery of histological biomarkers, bringing us a step closer to evidence-based pathology practice.

Learning-based algorithms can be utilized to learn prognostic features directly from images in a minimally biased manner (without explicit detection of TILs), and to integrate these with standard clinico-pathologic and genomic predictors. The approach of using deep learning algorithms to first detect and classify TILs and structures in histology, and then to calculate quantitative features of these objects, presents a way of closely modeling the clinical guidelines set forth by expert pathologists. Here, the power of learning algorithms is directed at providing highly accurate and robust detection and classification to enable reproducible and quantitative measurement. Although this approach is interpretable and provides a clear path for analytic validation, the limitation is that quantitative features are prescribed instead of learned. Recently, there have been

successful efforts to develop end-to-end prognostic deep learning models that learn to directly predict clinical outcomes from raw images without any intermediate classification of histologic objects like TILs^{17,92}. Although these end-to-end learning approaches have the potential to learn latent prognostic patterns (including those impossible to assess visually), they are less interpretable and thus the factors driving the predictions are currently unknown.

Finally, we would note that one of the key limitations of machine learning models, and deep learning models in particular, is their opaqueness. It is often the case that model accuracy comes at a cost to explainability, giving rise to the term “black box” often associated with deep learning. The problem with less explainable models is that key features driving output may not be readily identifiable to evaluate biologic plausibility, and hence the only safeguard against major flaws is extensive validation⁹³. Perhaps the most notorious consequence of this problem is “adversarial examples”, which are images that look natural to the human eye but that are specifically crafted (e.g., by malicious actors) to mislead deep learning models to make targeted misclassifications⁹⁴. Nevertheless, recent advances in deep learning research have substantially increased model interpretability, and have devised key model training strategies (e.g., generative adversarial neural networks) to increase performance robustness^{93,95–97}.

CONCLUSIONS

Advances in digital pathology and ML methodology have yielded expert-level performance in challenging diagnostic tasks. Evaluation of TILs in solid tumors is a highly suitable application for computational and computer-aided assessment, as it is both technically feasible and fills an unmet clinical need for objective and reproducible assessment. CTA algorithms need to account for the complexity involved in TIL-scoring procedures, and to closely follow guidelines for visual assessment where appropriate. TIL scoring needs to capture the concepts of stromal and intratumoral TILs and to account for confounding morphologies specific to different tumor sites, subtypes, and histologic patterns. Preanalytical factors related to imaging modality, staining procedure, and slide inclusion criteria are critical considerations, and robust analytical and clinical validation is key to adoption. In the clinical setting, CTA would ideally provide time- and cost-savings for pathologists, who face increasing demands for reporting biomarkers that are time-consuming to evaluate and subject to considerable inter- and intra- reader variability. In addition, CTA enables discovery of complex spatial patterns and genomic associations beyond the limits of visual scoring, and presents opportunities for precision medicine and scientific discovery.

Received: 15 July 2019; Accepted: 18 February 2020;

Published online: 12 May 2020

REFERENCES

- Piccart-Gebhart, M. et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or Trastuzumab Treatment Optimization Trial. *J. Clin. Oncol.* **34**, 1034–1042 (2016).
- von Minckwitz, G. et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. *N. Engl. J. Med.* **377**, 122–131 (2017).
- Denkert, C. et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. *J. Clin. Oncol.* **28**, 105–113 (2010).
- Savas, P. et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. *Nat. Rev. Clin. Oncol.* **13**, 228–241 (2016).
- Burns, P. B., Rohrich, R. J. & Chung, K. C. The levels of evidence and their role in evidence-based medicine. *Plast. Reconstr. Surg.* **128**, 305–310 (2011).
- Balic, M., Thomssen, C., Würstlein, R., Gnant, M. & Harbeck, N. St. Gallen/Vienna 2019: a brief summary of the consensus discussion on the optimal primary breast cancer treatment. *Breast Care* **14**, 103–110 (2019).
- Denkert, C. et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. *Mod. Pathol.* **29**, 1155–1164 (2016).
- Wein, L. et al. Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions. *Front. Oncol.* **7**, 156 (2017).
- Brambilla, E. et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. *J. Clin. Oncol.* **34**, 1223–1230 (2016).
- Hendry, S. et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 1: assessing the host immune response, tils in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. *Adv. Anat. Pathol.* **24**, 235–251 (2017).
- Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Ann. Oncol.* **26**, 259–271 (2015).
- Hendry, S. et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: tils in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. *Adv. Anat. Pathol.* **24**, 311–335 (2017).
- Brunyé, T. T., Mercan, E., Weaver, D. L. & Elmore, J. G. Accuracy is in the eyes of the pathologist: the visual interpretive process and diagnostic accuracy with digital whole slide images. *J. Biomed. Inform.* **66**, 171–179 (2017).
- Ehteshami Bejnordi, B. et al. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. *JAMA* **318**, 2199–2210 (2017).
- Tellez, D. et al. Whole-slide mitosis detection in H&E breast histology using PHH3 as a reference to train distilled stain-invariant convolutional networks. *IEEE Trans. Med. Imaging* (2018). <https://doi.org/10.1109/TMI.2018.2820199>
- Amgad, M. et al. Structured crowdsourcing enables convolutional segmentation of histology images. *Bioinformatics* **35**, 3461–3467 (2019).
- Mobadersany, P. et al. Predicting cancer outcomes from histology and genomics using convolutional networks. *Proc. Natl Acad. Sci. USA* **115**, E2970–E2979 (2018).
- Litjens, G. et al. A survey on deep learning in medical image analysis. *Med. Image Anal.* **42**, 60–88 (2017).
- Janowczyk, A. & Madabhushi, A. Deep learning for digital pathology image analysis: a comprehensive tutorial with selected use cases. *J. Pathol. Inform.* **7**, 29 (2016).
- Klauschen, F. et al. Scoring of tumor-infiltrating lymphocytes: from visual estimation to machine learning. *Semin. Cancer Biol.* **52**, 151–157 (2018).
- Barua, S. et al. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. *Lung Cancer* **117**, 73–79 (2018).
- Schalper, K. A. et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. *J. Natl. Cancer Inst.* **107**, dju435 (2015).
- Brown, J. R. et al. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. *Clin. Cancer Res.* **20**, 5995–6005 (2014).
- Saltz, J. et al. Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images. *Cell Rep.* **23**, 181–193.e7 (2018).
- Amgad, M. et al. Joint region and nucleus segmentation for characterization of tumor infiltrating lymphocytes in breast cancer. in *Medical Imaging 2019: Digital Pathology* (eds Tomaszewski, J. E. & Ward, A. D.) 20 (SPIE, 2019).
- Yuan, Y. et al. Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. *Sci. Transl. Med.* **4**, 157ra143 (2012).
- Basavanahally, A. N. et al. Computerized image-based detection and grading of lymphocytic infiltration in HER2+ breast cancer histopathology. *IEEE Trans. Biomed. Eng.* **57**, 642–653 (2010).
- Corredor, G. et al. Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non-small cell lung cancer. *Clin. Cancer Res.* **25**, 1526–1534 (2019).
- Yoon, H. H. et al. Intertumoral heterogeneity of CD3 and CD8 T-cell densities in the microenvironment of dna mismatch-repair-deficient colon cancers: implications for prognosis. *Clin. Cancer Res.* **25**, 125–133 (2019).
- Swiderska-Chadaj, Z. et al. Convolutional Neural Networks for Lymphocyte detection in Immunohistochemically Stained Whole-Slide Images. (2018).

31. Heindl, A. et al. Relevance of spatial heterogeneity of immune infiltration for predicting risk of recurrence after endocrine therapy of ER+ breast cancer. *J. Natl. Cancer Inst.* **110**, djj137 (2018).
32. Stoler, M. H. Advances in cervical screening technology. *Mod. Pathol.* **13**, 275–284 (2000).
33. Vis, J. Y. & Huisman, A. Verification and quality control of routine hematology analyzers. *Int. J. Lab. Hematol.* **38**, 100–109 (2016).
34. Perkel, J. M. Immunohistochemistry for the 21st century. *Science* **351**, 1098–1100 (2016).
35. Lloyd, M. C. et al. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: how reliable is it? *J. Pathol. Inform.* **1**, 29 (2010).
36. Holten-Rossing, H., Möller Talman, M.-L., Kristensson, M. & Vainer, B. Optimizing HER2 assessment in breast cancer: application of automated image analysis. *Breast Cancer Res. Treat.* **152**, 367–375 (2015).
37. Gavrielides, M. A., Gallas, B. D., Lenz, P., Badano, A. & Hewitt, S. M. Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computer-aided digital microscopy. *Arch. Pathol. Lab. Med.* **135**, 233–242 (2011).
38. Hamilton, P. W. et al. Digital pathology and image analysis in tissue biomarker research. *Methods* **70**, 59–73 (2014).
39. Dieci, M. V. et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immunology Biomarker Working Group on Breast Cancer. *Semin. Cancer Biol.* **52**, 16–25 (2018).
40. Finotello, F. & Trajanoski, Z. Quantifying tumor-infiltrating immune cells from transcriptomics data. *Cancer Immunol. Immunother.* **67**, 1031–1040 (2018).
41. Chakravarthy, A. et al. Pan-cancer deconvolution of tumour composition using DNA methylation. *Nat. Commun.* **9**, 3220 (2018).
42. Ács, B. et al. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. *Diagn. Pathol.* **12**, 20 (2017).
43. Yi, M. et al. Which threshold for ER positivity? a retrospective study based on 9639 patients. *Ann. Oncol.* **25**, 1004–1011 (2014).
44. Göranson, C. et al. Immunohistochemical characterization of lymphocytes in microscopic colitis. *J. Crohns. Colitis* **7**, e434–e442 (2013).
45. Pagès, F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet* **391**, 2128–2139 (2018).
46. Galon, J. et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. *J. Pathol.* **232**, 199–209 (2014).
47. Väyrynen, J. P. et al. An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer. *Virchows Arch.* **460**, 455–465 (2012).
48. Singh, U. et al. Analytical validation of quantitative immunohistochemical assays of tumor infiltrating lymphocyte biomarkers. *Biotech. Histochem.* **93**, 411–423 (2018).
49. Buisseret, L. et al. Tumor-infiltrating lymphocyte composition, organization and PD-1/PD-L1 expression are linked in breast cancer. *Oncoimmunology* **6**, e1257452 (2017).
50. Blom, S. et al. Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. *Sci. Rep.* **7**, 15580 (2017).
51. Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nat. Med.* **21**, 938–945 (2015).
52. Stanton, S. E., Adams, S. & Disis, M. L. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. *JAMA Oncol.* **2**, 1354–1360 (2016).
53. Janowczyk, A., Zuo, R., Gilmore, H., Feldman, M. & Madabhushi, A. HistoQC: an open-source quality control tool for digital pathology slides. *JCO Clin. Cancer Inf.* **3**, 1–7 (2019).
54. Hipp, J. et al. Computer aided diagnostic tools aim to empower rather than replace pathologists: Lessons learned from computational chess. *J. Pathol. Inform.* **2**, 25 (2011).
55. Gurcan, M. N. Histopathological image analysis: path to acceptance through evaluation. *Microsc. Microanal.* **22**, 1004–1005 (2016).
56. Fauzi, M. F. A. et al. Classification of follicular lymphoma: the effect of computer aid on pathologists grading. *BMC Med. Inform. Decis. Mak.* **15**, 115 (2015).
57. Madabhushi, A., Agner, S., Basavanahally, A., Doyle, S. & Lee, G. Computer-aided prognosis: predicting patient and disease outcome via quantitative fusion of multi-scale, multi-modal data. *Comput. Med. Imaging Graph.* **35**, 506–514 (2011).
58. Hayes, D. F. Precision medicine and testing for tumor biomarkers—are all tests born equal? *JAMA Oncol.* **4**, 773–774 (2018).
59. Selleck, M. J., Senthil, M. & Wall, N. R. Making meaningful clinical use of biomarkers. *Biomark. Insights* **12**, 11772719–17715236 (2017).
60. Masucci, G. V. et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. *J. Immunother. Cancer* **4**, 76 (2016).
61. Dobbin, K. K. et al. Validation of biomarkers to predict response to immunotherapy in cancer: volume II - clinical validation and regulatory considerations. *J. Immunother. Cancer* **4**, 77 (2016).
62. Pantanowitz, L. et al. Validating whole slide imaging for diagnostic purposes in pathology: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. *Arch. Pathol. Lab. Med.* **137**, 1710–1722 (2013).
63. Fda, M. Guidance for Industry and Food and Drug Administration Staff - Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices. (2016). Available at: <https://www.fda.gov/media/90791/download>.
64. US Food and Drug Administration. Device Advice for AI and Machine Learning Algorithms. NCIPhub - Food and Drug Administration. Available at: <https://nciphub.org/groups/eedapstudies/wiki/DeviceAdvice>. (Accessed: 4th July 2017).
65. Leo, P. et al. Evaluating stability of histomorphometric features across scanner and staining variations: prostate cancer diagnosis from whole slide images. *J. Med. Imaging (Bellingham)* **3**, 047502 (2016).
66. Pantanowitz, L., Liu, C., Huang, Y., Guo, H. & Rohde, G. K. Impact of altering various image parameters on human epidermal growth factor receptor 2 image analysis data quality. *J. Pathol. Inform.* **8**, 39 (2017).
67. Pantanowitz, L. et al. Twenty years of digital pathology: an overview of the road travelled, what is on the horizon, and the emergence of vendor-neutral archives. *J. Pathol. Inform.* **9**, 40 (2018).
68. Zarella, M. D., Yeoh, C., Breen, D. E. & Garcia, F. U. An alternative reference space for H&E color normalization. *PLoS ONE* **12**, e0174489 (2017).
69. Herrmann, M. D. et al. Implementing the DICOM standard for digital pathology. *J. Pathol. Inform.* **9**, 37 (2018).
70. Van Eycke, Y.-R., Allard, J., Salmon, I., Debeir, O. & Decaestecker, C. Image processing in digital pathology: an opportunity to solve inter-batch variability of immunohistochemical staining. *Sci. Rep.* **7**, 42964 (2017).
71. Tellez, D. et al. Quantifying the effects of data augmentation and stain color normalization in convolutional neural networks for computational pathology. <http://arxiv.org/abs/1902.06543> (2019).
72. Hou, L. et al. Unsupervised histopathology image synthesis. <http://arxiv.org/abs/1712.05021> (2017).
73. Steyerberg, E. W. & Harrell, F. E. Jr. Prediction models need appropriate internal, internal-external, and external validation. *J. Clin. Epidemiol.* **69**, 245–247 (2016).
74. Natrajan, R. et al. Microenvironmental heterogeneity parallels breast cancer progression: a histology-genomic integration analysis. *PLoS Med.* **13**, e1001961 (2016).
75. Loi, S. et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancer. *J. Clin. Oncol.* **37**, 559–569 (2019).
76. Beck, A. H. Open access to large scale datasets is needed to translate knowledge of cancer heterogeneity into better patient outcomes. *PLoS Med.* **12**, e1001794 (2015).
77. Litjens, G. et al. 1399 H&E-stained sentinel lymph node sections of breast cancer patients: the CAMELYON dataset. *Gigascience* **7**, gjy065 (2018).
78. US Food and Drug Administration. Year 2: High-throughput truthing of microscope slides to validate artificial intelligence algorithms analyzing digital scans of pathology slides: data (images + annotations) as an FDA-qualified medical device development tool (MDDT). Available at: <https://ncihub.org/groups/eedapstudies/wiki/HighthroughputTruthingYear2?version=2>.
79. Ørting, S. et al. A survey of crowdsourcing in medical image analysis. <http://arxiv.org/abs/1902.09159> (2019).
80. Hannun, A. Y. et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. *Nat. Med.* **25**, 65–69 (2019).
81. O'Connor, J. P. B. et al. Imaging biomarker roadmap for cancer studies. *Nat. Rev. Clin. Oncol.* **14**, 169–186 (2017).
82. Abramson, R. G. et al. Methods and challenges in quantitative imaging biomarker development. *Acad. Radiol.* **22**, 25–32 (2015).
83. Nalisenik, M. et al. Interactive phenotyping of large-scale histology imaging data with HistomicsML. *Sci. Rep.* **7**, 14588 (2017).
84. Kwolek, B. et al. Breast Cancer Classification on Histopathological Images Affected by Data Imbalance Using Active Learning and Deep Convolutional Neural Network: 28th International Conference on Artificial Neural Networks, Munich, Germany, September 17–19, 2019, Proceedings. in Artificial Neural Networks and Machine Learning—ICANN 2019: Workshop and Special Sessions (eds. Tetko, I. V., Kůrková, V., Karpov, P. & Theis, F.) 11731, 299–312 (Springer International Publishing, 2019).
85. U.S. Food and Drug Administration (FDA). Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing-Based In Vitro Diagnostics Intended to Aim in the Diagnosis of Suspected Germline Diseases. (2018). Available

at: <https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM509838.pdf>.

86. Mukherjee, A. et al. Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort. *NPJ Breast Cancer* **4**, 5 (2018).
87. Cooper, L. A. et al. PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective. *J. Pathol.* **244**, 512–524 (2018).
88. Anderson, R. Multiplex fluorescence in situ hybridization (M-FISH). *Methods Mol. Biol.* **659**, 83–97 (2010).
89. Longuespée, R. et al. Tissue proteomics for the next decade? Towards a molecular dimension in histology. *OMICS* **18**, 539–552 (2014).
90. Beck, A. H. et al. Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. *Sci. Transl. Med.* **3**, 108ra113 (2011).
91. Cantini, L. et al. Classification of gene signatures for their information value and functional redundancy. *NPJ Syst. Biol. Appl* **4**, 2 (2018).
92. Meier, A. et al. 77PEnd-to-end learning to predict survival in patients with gastric cancer using convolutional neural networks. *Ann. Oncol.* **29** <https://doi.org/10.1093/annonc/mdy269.07510.1093/annonc/mdy269.075> (2018).
93. Guidotti, R. et al. A survey of methods for explaining black box models. *ACM Comput. Surv.* **51**, 1–42 (2018).
94. Yuan, X., He, P., Zhu, Q. & Li, X. Adversarial examples: attacks and defenses for deep learning. *IEEE Trans. Neural Netw. Learn Syst.* **30**, 2805–2824 (2019).
95. Zhang, Q.-S. & Zhu, S.-C. Visual interpretability for deep learning: a survey. *Front. Inf. Technol. Electron. Eng.* **19**, 27–39 (2018).
96. Yousefi, S. et al. Predicting clinical outcomes from large scale cancer genomic profiles with deep survival models. *Sci. Rep.* **7**, 11707 (2017).
97. Yi, X., Walia, E. & Babyn, P. Generative adversarial network in medical imaging: a review. *Med. Image Anal.* **58**, 101552 (2019).

ACKNOWLEDGEMENTS

L.A.D.C. is supported in part by the National Institutes of Health National Cancer Institute (NCI) grants U01CA220401 and U24CA19436201. R.S. is supported by the Breast Cancer Research Foundation (BCRF), grant No. 17-194. J.S. is supported in part by NCI grants UG3CA225021 and U24CA215109. A.M. is supported in part by NCI grants 1U24CA199374-01, R01CA202752-01A1, R01CA208236-01A1, R01 CA216579-01A1, R01 CA220581-01A1, 1U01 CA239055-01, National Center for Research Resources under award number 1 C06 RR12463-01, VA Merit Review Award IBX004121A from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service, the DOD Prostate Cancer Idea Development Award (W81XWH-15-1-0558), the DOD Lung Cancer Investigator-Initiated Translational Research Award (W81XWH-18-1-0440), the DOD Peer Reviewed Cancer Research Program (W81XWH-16-1-0329), the Ohio Third Frontier Technology Validation Fund, the Wallace H. Coulter Foundation Program in the Department of Biomedical Engineering and the Clinical and Translational Science Award Program (CTSA) at Case Western Reserve University. S.G. is supported by Susan G Komen Foundation (CCR CCR18547966) and a Young Investigator Grant from the Breast Cancer Alliance. T.O.N. receives funding support from the Canadian Cancer Society. M.M.S. is supported by P30 CA16672 DHHS/NCI Cancer Center Support Grant (CCSG). A.S. is supported in part by NCI grants 1UG3CA225021, 1U24CA215109, and Leidos 14 × 138. This work includes contributions from, and was reviewed by, individuals at the F.D.A. This work has been approved for publication by the agency, but it does not necessarily reflect official agency policy. Certain commercial materials and equipment are identified in order to adequately specify experimental procedures. In no case does such identification imply recommendation or endorsement by the FDA, nor does it imply that the items identified are necessarily the best available for the purpose. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the US Department of Veterans Affairs, the Department of Defense, the United States Government, or other governments or entities. The following is a list of current members of the International Immuno-Oncology Working Group (TILs Working Group). Members contributed to the manuscript through discussions, including at the yearly TIL-WG meeting, and have reviewed and provided input on the manuscript. The authors alone are responsible for the views expressed in the work of the TILs Working Group and they do not necessarily represent the decisions, policy or views of their employer.

AUTHOR CONTRIBUTIONS

This report is produced as a result of discussion and consensus by members of the International Immuno-Oncology Biomarker Working Group (TILs Working Group). All

authors have contributed to: 1) the conception or design of the work, 2) drafting the work or revising it critically for important intellectual content, 3) final approval of the completed version, 4) accountability for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

COMPETING INTERESTS

J.T. is funded by Visiopharm A/S, Denmark. A.M. is an equity holder in Elucid Bioimaging and in Inspirata Inc. He is also a scientific advisory consultant for Inspirata Inc. In addition he has served as a scientific advisory board member for Inspirata Inc, AstraZeneca, Bristol Meyers-Squibb and Merck. He also has sponsored research agreements with Philips and Inspirata Inc. His technology has been licensed to Elucid Bioimaging and Inspirata Inc. He is also involved in an NIH U24 grant with PathCore Inc, and three different R01 grants with Inspirata Inc. S.R.L. received travel and educational funding from Roche/Ventana. A.J.L. serves as a consultant for BMS, Merck, AZ/Medimmune, and Genentech. He is also provides consulting and advisory work for many other companies not relevant to this work. FPL does consulting for AstraZeneca, BMS, Roche, MSD Pfizer, Novartis, Sanofi, and Lilly. S.Ld.H., A.K., M.K., U.K., and M.B. are employees of Roche. J.M.S.B. is consultant for Insight Genetics, BioNTech AG, Biothernostics, Pfizer, RNA Diagnostics, and OncoXchange. He received funding from Thermo Fisher Scientific, Genoptix, Agendia, NanoString technologies, Stratifyer GmbH, and Biothernostics. L.F.S.K. is a consultant for Roche and Novartis. J.K.K. and A.H.B. are employees of PathAI. D.L.R. is on the advisory board for Amgen, Astra Xeneca, Cell Signaling Technology, Cepheid, Daiichi Sankyo, GSK, Konica/Minolta, Merck, Nanostring, Perkin Elmer, Roche/Ventana, and Ultivue. He has received research support from AstraZeneca, Cepheid, Navigate BioPharma, NextCure, Lilly, Ultivue, Roche/Ventana, Akoya/Perkin Elmer, and Nanostring. He also has financial conflicts of interest with BMS, Biocept, PixelGear, and Rarecyte. S.G. is a consultant for and/or receives funding from Eli Lilly, Novartis, and G1 Therapeutics. J.A.W.M.vdL. is a member of the scientific advisory boards of Philips, the Netherlands and ContextVision, Sweden, and receives research funding from Philips, the Netherlands and Sectra, Sweden. S.A. is a consultant for Merck, Genentech, and BMS, and receives funding from Merck, Genentech, BMS, Novartis, Celgene, and Amgen. T.O.N. has consulted for Nanostring, and has intellectual property rights and ownership interests from Bioclassifier LLC. S.L. receives research funding to her institution from Novartis, Bristol Meyers-Squibb, Merck, Roche-Genentech, Puma Biotechnology, Pfizer and Eli Lilly. She has acted as consultant (not compensated) to Seattle Genetics, Pfizer, Novartis, BMS, Merck, AstraZeneca and Roche-Genentech. She has acted as consultant (paid to her institution) to Aduro Biotech. J.H. is director and owner of Slide Score BV. M.M.S. is a medical advisory board member of OpraScan. R.S. has received research support from Merck, Roche, Puma; and travel/congress support from AstraZeneca, Roche and Merck; and he has served as an advisory board member of BMS and Roche and consults for BMS.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to R.S. or L.A.D.C.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020

Mohamed Amgad¹, Elisabeth Specht Stovgaard², Eva Balslev², Jeppe Thagaard^{3,4}, Weijie Chen⁵, Sarah Dudgeon⁵, Ashish Sharma⁶, Jennifer K. Kerner⁶, Carsten Denkert^{7,8,9}, Yinyin Yuan^{10,11}, Khalid AbdulJabbar^{10,11}, Stephan Wienert⁷, Peter Savas^{12,13}, Leonie Voorwerk¹⁴, Andrew H. Beck⁶, Anant Madabhushi^{15,16}, Johan Hartman¹⁷, Manu M. Sebastian¹⁸, Hugo M. Horlings¹⁹, Jan Hudeček²⁰, Francesco Ciompi²¹, David A. Moore²², Rajendra Singh²³, Elvire Roblin²⁴, Marcelo Luiz Balancin²⁵, Marie-Christine Mathieu²⁶, Jochen K. Lennerz²⁷, Pawan Kirtani²⁸, I-Chun Chen²⁹, Jeremy P. Braybrooke^{30,31}, Giancarlo Pruner³², Sandra Demaria³³, Sylvia Adams³⁴, Stuart J. Schnitt³⁵, Sunil R. Lakhani³⁶, Federico Rojo^{37,38}, Laura Comerma^{37,38}, Sunil S. Badve³⁹, Mehrnoush Khojasteh⁴⁰, W. Fraser Symmans⁴¹, Christos Sotiriou^{42,43}, Paula Gonzalez-Ericsson⁴⁴, Katherine L. Pogue-Geile⁴⁵, Rim S. Kim⁴⁵, David L. Rimm⁴⁶, Giuseppe Viale⁴⁷, Stephen M. Hewitt⁴⁸, John M. S. Bartlett^{49,50}, Frédérique Penault-Llorca^{51,52}, Shom Goel⁵³, Huang-Chun Lien⁵⁴, Sibylle Loibl⁵⁵, Zuzana Kos⁵⁶, Sherene Loi^{13,57}, Matthew G. Hanna⁵⁸, Stefan Michiels^{59,60}, Marleen Kok^{61,62}, Torsten O. Nielsen⁶³, Alexander J. Lazar^{41,64,65,66}, Zsuzsanna Bago-Horvath⁶⁷, Loes F. S. Kooreman^{68,69}, Jeroen A. W. M. van der Laak^{21,70}, Joel Saltz⁷¹, Brandon D. Gallas⁶⁵, Uday Kurkure⁶⁵, Michael Barnes⁷², Roberto Salgado^{12,73}, Lee A. D. Cooper⁷⁴ and International Immuno-Oncology Biomarker Working Group

¹Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, USA. ²Department of Pathology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark. ³DTU Compute, Department of Applied Mathematics, Technical University of Denmark, Lyngby, Denmark. ⁴Visiopharm A/S, Hørsholm, Denmark. ⁵FDA/CDRH/OSEL/Division of Imaging, Diagnostics, and Software Reliability, Silver Spring, MD, USA. ⁶PathAI, Cambridge, MA, USA. ⁷Institut für Pathologie, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Philipps-Universität Marburg, Marburg, Germany. ⁸Institute of Pathology, Philipps-University Marburg, Marburg, Germany. ⁹German Cancer Consortium (DKTK), Partner Site Charité, Berlin, Germany. ¹⁰Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK. ¹¹Division of Molecular Pathology, The Institute of Cancer Research, London, UK. ¹²Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia. ¹³Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia. ¹⁴Department of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ¹⁵Case Western Reserve University, Department of Biomedical Engineering, Cleveland, OH, USA. ¹⁶Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH, USA. ¹⁷Department of Oncology and Pathology, Karolinska Institutet and University Hospital, Solna, Sweden. ¹⁸Departments of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ¹⁹Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ²⁰Department of Research IT, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ²¹Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. ²²Department of Pathology, UCL Cancer Institute, London, UK. ²³Department of Pathology and Laboratory Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ²⁴Université Paris-Saclay, Univ. Paris-Sud, Villejuif, France. ²⁵Department of Pathology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil. ²⁶Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France. ²⁷Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. ²⁸Department of Histopathology, Manipal Hospitals Dwarka, New Delhi, India. ²⁹Department of Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. ³⁰Nuffield Department of Population Health, University of Oxford, Oxford, UK. ³¹Department of Medical Oncology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK. ³²Pathology Department, Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, School of Medicine, Milan, Italy. ³³Weill Cornell Medical College, New York, NY, USA. ³⁴Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USA. ³⁵Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. ³⁶The University of Queensland Centre for Clinical Research and Pathology Queensland, Brisbane, Australia. ³⁷Pathology Department, CIBERONC-Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain. ³⁸GEICAM-Spanish Breast Cancer Research Group, Madrid, Spain. ³⁹Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. ⁴⁰Roche Tissue Diagnostics, Digital Pathology, Santa Clara, CA, USA. ⁴¹Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁴²Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium. ⁴³ULB-Cancer Research Center (U-CRC) Université Libre de Bruxelles, Brussels, Belgium. ⁴⁴Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. ⁴⁵NRG Oncology/NSABP, Pittsburgh, PA, USA. ⁴⁶Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. ⁴⁷Department of Pathology, IEO, European Institute of Oncology IRCCS & State University of Milan, Milan, Italy. ⁴⁸Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. ⁴⁹Ontario Institute for Cancer Research, Toronto, ON, Canada. ⁵⁰Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK. ⁵¹Department of Pathology and Molecular Pathology, Centre Jean Perrin, Clermont-Ferrand, France. ⁵²UMR INSERM 1240, Université Clermont Auvergne, Clermont-Ferrand, France. ⁵³Victorian Comprehensive Cancer Centre building, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. ⁵⁴Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan. ⁵⁵German Breast Group, c/o GBG-Forschungs GmbH, Neu-Isenburg, Germany. ⁵⁶Department of Pathology, BC Cancer, Vancouver, British Columbia, Canada. ⁵⁷Peter MacCallum Cancer Centre, Melbourne, Australia. ⁵⁸Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ⁵⁹Gustave Roussy, Université Paris-Saclay, Villejuif, France. ⁶⁰Université Paris-Sud, Institut National de la Santé et de la Recherche Médicale, Villejuif, France. ⁶¹Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ⁶²Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ⁶³University of British Columbia, Vancouver, British Columbia, Canada. ⁶⁴Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁶⁵Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁶⁶Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁶⁷Department of Pathology, Medical University of Vienna, Vienna, Austria. ⁶⁸GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands. ⁶⁹Department of Pathology, Maastricht University Medical Centre, Maastricht, The Netherlands. ⁷⁰Center for Medical Image Science and Visualization, Linköping University, Linköping, Sweden. ⁷¹Department of Biomedical Informatics, Stony Brook University, Stony Brook, NY, USA. ⁷²Roche Diagnostics Information Solutions, Belmont, CA, USA. ⁷³Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium. ⁷⁴Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. [✉]email: roberto@salgado.be lee.cooper@northwestern.edu

INTERNATIONAL IMMUNO-ONCOLOGY BIOMARKER WORKING GROUP

Aini Hyytiäinen⁷⁵, Akira I. Hida⁷⁶, Alastair Thompson⁷⁷, Alex Lefevre⁷⁸, Allen Gown⁷⁹, Amy Lo⁸⁰, Anna Sapino⁸¹, Andre Moreira⁸², Andrea Richardson⁸³, Andrea Vingiani⁸⁴, Andrew M. Bellizzi⁸⁵, Andrew Tutt⁸⁶, Angel Guerrero-Zotano⁸⁷, Anita Grigoriadis^{88,89}, Anna Ehinger⁹⁰, Anna C. Garrido-Castro⁹¹, Anne Vincent-Salomon⁹², Anne-Vibeke Laenkholtm⁹³, Ashley Cimino-Mathews⁹⁴, Ashok Srinivasan⁹⁵, Balazs Acs⁹⁶, Baljit Singh⁹⁷, Benjamin Calhoun⁹⁸, Benjamin Haibe-Kans⁹⁹, Benjamin Solomon¹⁰⁰, Bibhusal Thapa¹⁰¹, Brad H. Nelson¹⁰², Carlos Castaneda^{103,104}, Carmen Ballesteros-Merino¹⁰⁵, Carmen Criscitiello¹⁰⁶, Carolien Boeckx⁷⁸, Cecile Colpaert¹⁰⁷, Cecily Quinn¹⁰⁸, Chakra S. Chennubhotla¹⁰⁹, Charles Swanton¹¹⁰, Cinzia Solinas¹¹¹, Crispin Hiley¹¹⁰, Damien Drubay^{59,60}, Daniel Bethmann¹¹², Deborah A. Dillon¹¹³, Denis Larsimont¹¹⁴, Dhanusha Sabanathan¹¹⁵, Dieter Peeters¹¹⁶, Dimitrios Zardavas¹¹⁷, Doris Höflmayer¹¹⁸, Douglas B. Johnson¹¹⁹, E. Aubrey Thompson¹²⁰, Edi Brogi⁵⁸, Edith Perez¹²¹, Ehab A. ElGaby¹²², Elizabeth F. Blackley¹⁰⁰, Emily Reisenbichler⁴⁶, Enrique Bellolio^{123,124}, Ewa Chmielik¹²⁵, Fabien Gaire¹²⁶, Fabrice Andre¹²⁷, Fang-I Lu¹²⁸, Farid Azmoudeh-Ardalan¹²⁹, Forbuis Tina Gruosso¹³⁰, Franklin Peale¹³¹, Fred R. Hirsch¹³², Frederick Klauschen¹³³, Gabriela Acosta-Haab¹³⁴, Gelareh Farshid¹³⁵, Gert van den Eynden¹³⁶, Giuseppe Curigliano^{137,138}, Giuseppe Floris^{139,140}, Glenn Broeckx¹⁴¹, Harmut Koeppen⁸⁰, Harry R. Haynes¹⁴², Heather McArthur¹⁴³, Heikki Joensuu¹⁴⁴, Helena Olofsson¹⁴⁵, Ian Cree¹⁴⁶, Iris Nederlof¹⁴⁷, Isabel Frahm¹⁴⁸, Iva Brcic¹⁴⁹, Jack Chan¹⁵⁰, Jacqueline A. Hall¹⁵¹, James Ziai⁸⁰, Jane Brock¹⁵², Jelle Wesseling¹⁵³,

Jennifer Giltne⁸⁰, Jerome Lemonnier¹⁵⁴, Jiping Zha¹⁵⁵, Joana M. Ribeiro¹⁵⁶, Jodi M. Carter¹⁵⁷, Johannes Hainfellner¹⁵⁸, John Le Quesne¹⁵⁹, Jonathan W. Juco¹⁶⁰, Jorge Reis-Filho^{58,161}, Jose van den Berg¹⁶², Joselyn Sanchez¹⁰⁴, Joseph Sparano¹⁶³, Joël Cucherousset¹⁶⁴, Juan Carlos Araya¹²³, Julien Adam¹⁶⁵, Justin M. Balko¹⁶⁶, Kai Saeger¹⁶⁷, Kalliopi Siziopikou¹⁶⁸, Karen Willard-Gallo¹⁶⁹, Karolina Sikorska¹⁷⁰, Karsten Weber¹⁷¹, Keith E. Steele¹⁵⁵, Kenneth Emancipator¹⁶⁰, Khalid El Bairi¹⁷², Kim R. M. Blenman¹⁷³, Kimberly H. Allison¹⁷⁴, Koen K. van de Vijver¹⁷⁵, Konstany Korski¹⁷⁶, Lajos Pusztai¹⁷³, Laurence Buisseret¹⁶⁹, Leming Shi¹⁷⁷, Liu Shi-wei¹⁷⁸, Luciana Molinero¹³¹, M. Valeria Estrada¹⁷⁹, Maartje van Seijen¹⁸⁰, Magali Lacroix-Triki¹⁸¹, Maggie C. U. Cheang¹⁸², Maise al Bakir¹¹⁰, Marc van de Vijver¹⁸³, Maria Vittoria Dieci¹⁸⁴, Marlon C. Rebelatto¹⁵⁵, Martine Piccart¹⁸⁵, Matthew P. Goetz¹²¹, Matthias Preusser¹⁵⁸, Melinda E. Sanders¹⁸⁶, Meredith M. Regan^{187,188}, Michael Christie¹⁸⁹, Michael Misialek¹⁹⁰, Michail Ignatiadis¹⁹¹, Michiel de Maaker¹⁸⁰, Mieke van Bockstal¹⁹², Miluska Castillo¹⁰⁴, Nadia Harbeck¹⁹³, Nadine Tung¹⁹⁴, Nele Laudus¹⁹⁵, Nicolas Sirtaine¹⁹⁶, Nicole Burchardi¹⁹⁷, Nils Ternes¹⁹⁸, Nina Radosevic-Robin¹⁹⁹, Oleg Gluz²⁰⁰, Oliver Grimm¹²⁶, Paolo Nuciforo²⁰¹, Paul Jank²⁰², Petar Jelinic¹⁶⁰, Peter H. Watson²⁰³, Prudence A. Francis^{13,57}, Prudence A. Russell²⁰⁴, Robert H. Pierce²⁰⁵, Robert Hills²⁰⁶, Roberto Leon-Ferre¹²¹, Roland de Wind¹⁹⁶, Ruohong Shui²⁰⁷, Sabine Declercq²⁰⁸, Sam Leung⁶³, Sami Tabbarah²⁰⁹, Sandra C. Souza²¹⁰, Sandra O'Toole²¹¹, Sandra Swain²¹², Scooter Willis²¹³, Scott Ely²¹⁴, Seong-Rim Kim²¹⁵, Shahinaz Bedri²¹⁶, Sheeba Irshad^{217,218}, Shi-Wei Liu²¹⁹, Shona Hendry²²⁰, Simonetta Bianchi²²¹, Sofia Bragança²²², Soonmyung Paik⁹⁵, Stephen B. Fox²²⁰, Stephen J. Luen¹², Stephen Naber²²³, Sua Luz²²⁴, Susan Fineberg²²⁵, Teresa Soler²²⁶, Thomas Gevaert²²⁷, Timothy d'Alfons⁵⁸, Tom John²²⁸, Tomohagu Sugie²²⁹, Veerle Bossuyt²³⁰, Venkata Manem⁹⁹, Vincente Peg Cámaea²³¹, Weida Tong²³², Wentao Yang²⁰⁷, William T. Tran²⁰⁹, Yihong Wang²³³, Yves Allory²³⁴ and Zaheed Husain²³⁵

⁷⁵Department of Oral and Maxillofacial Diseases, Helsinki, Finland. ⁷⁶Department of Pathology, Matsuyama Shimin Hospital, Matsuyama, Japan. ⁷⁷Surgical Oncology, Baylor College of Medicine, Texas, USA. ⁷⁸Roche Diagnostics, Machele, Belgium. ⁷⁹PhenoPath Laboratories, Seattle, USA. ⁸⁰Research Pathology, Genentech Inc., South San Francisco, USA. ⁸¹Department of Medical Sciences, University of Turin, Italy and Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy. ⁸²Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University, New York, NY, USA. ⁸³Department of Pathology, Johns Hopkins Hospital, Baltimore, USA. ⁸⁴Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy. ⁸⁵Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, USA. ⁸⁶Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK. ⁸⁷Department of Oncology, Instituto Valenciano de Oncología, Valencia, Spain. ⁸⁸Cancer Bioinformatics Lab, Cancer Centre at Guy's Hospital, London, UK. ⁸⁹School of Life Sciences and Medicine, King's College London, London, UK. ⁹⁰Department of Clinical Genetics and Pathology, Skåne University Hospital, Lund University, Lund, Sweden. ⁹¹Dana-Farber Cancer Institute, Boston, MA, USA. ⁹²Institut Curie, Paris Sciences Lettres Université, Inserm U934, Department of Pathology, Paris, France. ⁹³Department of Surgical Pathology Zealand University Hospital, Køge, Denmark. ⁹⁴Departments of Pathology and Oncology, The Johns Hopkins Hospital, Baltimore, USA. ⁹⁵National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA, USA. ⁹⁶Department of Pathology, Karolinska Institute, Solna, Sweden. ⁹⁷Department of Pathology, New York University Langone Medical Centre, New York, USA. ⁹⁸Department of Pathology and Laboratory Medicine, UNC School of Medicine, Columbia, USA. ⁹⁹Québec Heart and Lung Institute Research Center, Laval University, Quebec city, Quebec, Canada. ¹⁰⁰Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. ¹⁰¹Department of Medicine, University of Melbourne, Parkville, Australia. ¹⁰²Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada. ¹⁰³Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú. ¹⁰⁴Department of Research, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Peru. ¹⁰⁵Providence Cancer Research Center, Portland, Oregon, USA. ¹⁰⁶Department of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy. ¹⁰⁷Department of Pathology, AZ Turnhout, Turnhout, Belgium. ¹⁰⁸Department of Pathology, St Vincent's University Hospital and University College Dublin, Dublin, Ireland. ¹⁰⁹Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, USA. ¹¹⁰Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK. ¹¹¹Azienda AUSL, Regional Hospital of Aosta, Aosta, Italy. ¹¹²University Hospital Halle (Saale), Institute of Pathology, Halle, Saale, Germany. ¹¹³Department of Pathology, Brigham and Women's Hospital, Boston, MA Department of Pathology, Dana Farber Cancer Institute, Boston, MA, USA. ¹¹⁴Department of Pathology, Jules Bordet Institute, Brussels, Belgium. ¹¹⁵Department of Clinical Medicine, Macquarie University, Sydney, Australia. ¹¹⁶HistoGeneX NV, Antwerp, Belgium and AZ Sint-Maarten Hospital, Mechelen, Belgium. ¹¹⁷Oncology Clinical Development, Bristol-Myers Squibb, Princeton, USA. ¹¹⁸Institut für Pathologie, UK Hamburg, Hamburg, Germany. ¹¹⁹Department of Medicine, Vanderbilt University Medical Centre, Nashville, USA. ¹²⁰Department of Cancer Biology, Mayo Clinic, Jacksonville, USA. ¹²¹Department of Oncology, Mayo Clinic, Rochester, USA. ¹²²Roche, Tucson, USA. ¹²³Department of Pathology, Universidad de La Frontera, Temuco, Chile. ¹²⁴Departamento de Anatomía Patológica, Universidad de La Frontera, Temuco, Chile. ¹²⁵Tumor Pathology Department, Maria Skłodowska-Curie Memorial Cancer Center, Gliwice, Poland. ¹²⁶Pathology and Tissue Analytics, Roche, Machele, Belgium. ¹²⁷Department of Medical Oncology, Gustave Roussy, Villejuif, France. ¹²⁸Sunnybrook Health Sciences Centre, Toronto, Canada. ¹²⁹Tehran University of Medical Sciences, Tehran, Iran. ¹³⁰Translational Research, Montreal, Canada. ¹³¹Oncology Biomarker Development, Genentech-Roche, Machele, Belgium. ¹³²Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA. ¹³³Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany. ¹³⁴Department of Pathology, Hospital de Oncología Maria Curie, Buenos Aires, Argentina. ¹³⁵Directorate of Surgical Pathology, SA Pathology, Adelaide, Australia. ¹³⁶Department of Pathology, GZA-ZNA Hospitals, Wilrijk, Belgium. ¹³⁷University of Milano, Istituto Europeo di Oncologia, IRCCS, Milano, Italy. ¹³⁸Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology IRCCS, Milan, Italy. ¹³⁹Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research, Leuven, Belgium. ¹⁴⁰KU Leuven- University Hospitals Leuven, Department of Pathology, Leuven, Belgium. ¹⁴¹Department of Pathology, University Hospital Antwerp, Antwerp, Belgium. ¹⁴²Translational Health Sciences, Department of Cellular Pathology, North Bristol NHS Trust, University of Bristol, Bristol, UK. ¹⁴³Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA. ¹⁴⁴Helsinki University Central Hospital, Helsinki, Finland. ¹⁴⁵Department of Clinical Pathology, Akademiska University Hospital, Uppsala, Sweden. ¹⁴⁶International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France. ¹⁴⁷Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ¹⁴⁸Department of Pathology, Sanatorio Mater Dei, Buenos Aires, Argentina. ¹⁴⁹Institute of Pathology, Medical University of Graz, Graz, Austria. ¹⁵⁰Department of Oncology, National Cancer Centre, Singapore, Singapore. ¹⁵¹Vivactiv Ltd, Bellingdon, Bucks, UK. ¹⁵²Department of Pathology, Brigham and Women's Hospital, Boston, USA. ¹⁵³Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. ¹⁵⁴R&D UNICANCER, Paris, France. ¹⁵⁵Translational Sciences, MedImmune, Gaithersburg, USA. ¹⁵⁶Breast Unit, Champalimaud Clinical Centre, Lisboa, Portugal. ¹⁵⁷Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA. ¹⁵⁸Department of Medicine, Clinical Division of Oncology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna, Austria. ¹⁵⁹Leicester Cancer Research Centre, University of Leicester, Leicester, and MRC Toxicology Unit, University of Cambridge, Cambridge, UK. ¹⁶⁰Merck & Co., Inc, Kenilworth, NJ, USA. ¹⁶¹Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ¹⁶²Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ¹⁶³Department of Medicine, Department of Obstetrics & Gynecology and Women's Health, Albert Einstein Medical Center, Bronx, USA. ¹⁶⁴GHI Le Raincy-Montfermeil, Chelles, Ile-de-France, France. ¹⁶⁵Department of Pathology, Gustave Roussy, Grand Paris, France. ¹⁶⁶Departments of Medicine and Cancer Biology, Vanderbilt University Medical Centre, Nashville, USA. ¹⁶⁷Vm Scope, Berlin, Germany. ¹⁶⁸Department of Pathology, Breast Pathology Section, Northwestern University, Chicago, USA. ¹⁶⁹Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. ¹⁷⁰Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ¹⁷¹German Breast Group, Neu-Isenburg, Germany. ¹⁷²Cancer Biomarkers Working Group, Faculty of Medicine and Pharmacy, Université Mohamed Premier, Oujda, Morocco. ¹⁷³Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale School of Medicine, New Haven, CT, USA. ¹⁷⁴Pathology Department, Stanford University Medical Center, Stanford, USA. ¹⁷⁵Department of Pathology, University Hospital Ghent, Ghent, Belgium. ¹⁷⁶Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg, Germany. ¹⁷⁷Center for Pharmacogenomics and Fudan-Zhangjiang, Center for Clinical Genomics School of Life Sciences and Shanghai Cancer Center, Fudan University, Fudan, China. ¹⁷⁸Sichuan Cancer Hospital, Chengdu, China. ¹⁷⁹Biorepository and Tissue Technology Shared Resources, University of California San Diego, San Diego, USA. ¹⁸⁰Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ¹⁸¹Department of Pathology, Gustave Roussy, Villejuif, France. ¹⁸²Institute of Cancer Research Clinical Trials and Statistics Unit, The Institute of Cancer Research, Surrey, UK. ¹⁸³Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands. ¹⁸⁴Department of Surgery, Oncology and Gastroenterology, University of

Padova, Padua, Italy. ¹⁸⁵Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. ¹⁸⁶Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Centre, Nashville, USA. ¹⁸⁷Harvard Medical School, Boston, USA. ¹⁸⁸Division of Biostatistics, Dana-Farber Cancer Institute, Boston, USA. ¹⁸⁹Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville, Australia. ¹⁹⁰Vernon Cancer Center, Newton-Wellesley Hospital, Newton, USA. ¹⁹¹Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. ¹⁹²Department of Pathology, Cliniques universitaires Saint-Luc, Brussels, Belgium. ¹⁹³Breast Center, Dept. OB&GYN and CCC (LMU), University of Munich, Munich, Germany. ¹⁹⁴Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, USA. ¹⁹⁵University of Leuven, Leuven, Belgium. ¹⁹⁶Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. ¹⁹⁷German Breast Group GmbH, Neu-Isenburg, Germany. ¹⁹⁸Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Université-Paris Sud, Université Paris-Saclay, Villejuif, France. ¹⁹⁹Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France. ²⁰⁰Johanniter GmbH - Evangelisches Krankenhaus Bethesda Mönchengladbach, West German Study Group, Mönchengladbach, Germany. ²⁰¹Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain. ²⁰²Department of Pathology, University of Marburg, Marburg, Germany. ²⁰³Department of Pathology and Laboratory Medicine, University of British Columbia, Columbia, USA. ²⁰⁴Department of Anatomical Pathology, St Vincent's Hospital Melbourne, Fitzroy, Australia. ²⁰⁵Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, USA. ²⁰⁶Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford, Oxford, UK. ²⁰⁷Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China. ²⁰⁸Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium. ²⁰⁹Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Research Institute, Toronto, Canada. ²¹⁰Oncology Merck & Co, New Jersey, USA. ²¹¹The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Australian Clinical Labs, Darlinghurst, Australia. ²¹²Georgetown University Medical Center, Washington DC, USA. ²¹³Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD, USA. ²¹⁴Translational Medicine, Bristol-Myers Squibb, Princeton, USA. ²¹⁵National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, USA. ²¹⁶Anatomic Pathology, Boston, MA, USA. ²¹⁷King's College London, London, UK. ²¹⁸Guy's Hospital, London, UK. ²¹⁹Peking University First Hospital Breast Disease Center, Beijing, China. ²²⁰Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia. ²²¹Dipartimento di Scienze della Salute (DSS), Firenze, Italy. ²²²Department of Oncology, Champalimaud Clinical Centre, Lisbon, Portugal. ²²³Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, USA. ²²⁴Department of Pathology, Fundación Valle del Lili, Cali, Colombia. ²²⁵Department of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, USA. ²²⁶Department of Pathology, University Hospital of Bellvitge, Oncobell, IDIBELL, L'Hospitalet del Llobregat, Barcelona 08908 Catalonia, Spain. ²²⁷Department of Development and Regeneration, Laboratory of Experimental Urology, KU Leuven, Leuven, Belgium. ²²⁸Department of Medical Oncology, Austin Health, Heidelberg, Australia. ²²⁹Department of Surgery, Kansai Medical University to Tomoharu Sugie, Breast Surgery, Kansai Medical University Hospital, Hirakata, Japan. ²³⁰Department of Pathology, Massachusetts General Hospital, Boston, USA. ²³¹Pathology Department, H.U. Vall d'Hebron, Barcelona, Spain. ²³²Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, Wuhan, USA. ²³³Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Providence, USA. ²³⁴Université Paris-Est, Créteil, France. ²³⁵Praava Health, Dhaka, Bangladesh.